AOXING PHARMACEUTICAL COMPANY, INC. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - February 14, 2012



Attached files
FileFilename
EXCEL - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.Financial_Report.xls
10-Q - AOXING PHARMACEUTICAL COMPANY, INC. 10Q 2011-12-31 - AOXING PHARMACEUTICAL COMPANY, INC.aoxingphar10q.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R9.htm
EX-32 - RULE 13A-14(B) CERTIFICATION - AOXING PHARMACEUTICAL COMPANY, INC.aoxingpharexh32.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION ? CEO - AOXING PHARMACEUTICAL COMPANY, INC.aoxingpharexh311.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION ? CFO - AOXING PHARMACEUTICAL COMPANY, INC.aoxingpharexh312.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - AOXING PHARMACEUTICAL COMPANY, INC.R10.htm
v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
6 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Net loss $ (1,105,003) $ (704,194)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization (production and nonproduction) 588,120 576,962
Deferred income tax (120,858) (392,210)
Common stock issued for services 359,509 252,559
Change in fair value of warrants and derivative liability (1,161) (1,117,023)
Equity in (income) loss of joint venture, net 78,930  
Net loss attributable to non-controlling interests (23,779) (78,442)
Change in accounts receivable (286,675) (469,755)
Change in inventories 21,583 (10,874)
Change in prepaid expenses and other current assets (266,202) (134,167)
Change in accounts payable 34,932 449,032
Change in accrued expenses and other current liabilities 570,135 298,371
NET CASH USED IN OPERATING ACTIVITIES (150,469) (1,329,741)
INVESTING ACTIVITIES:    
Acquisition of property and equipment (40,071) (1,044,528)
Loan repayment from unrelated parties   291,049
NET CASH USED IN INVESTING ACTIVITIES (40,071) (753,479)
Short-term borrowings, net of repayment 3,124,902 680,601
Proceeds from other borrowings 71,404 39,324
Proceeds from (Repayment of) loans from related party (1,672) 49,457
NET CASH PROVIDED BY FINANCING ACTIVITIES 3,194,634 769,382
EFFECT OF EXCHANGE RATE ON CASH 42,135 136,874
INCREASE (DECREASE) IN CASH 3,046,229 (1,176,964)
CASH - BEGINNING OF PERIOD 2,770,744 3,985,710
CASH - END OF PERIOD 5,816,973 2,808,746
Cash paid for interest 916,376 588,227
Cash paid for income taxes      

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by AOXING PHARMACEUTICAL COMPANY, INC. and has no official or unofficial affiliation with AOXING PHARMACEUTICAL COMPANY, INC.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.